{"id":23,"date":"2026-10-28T11:42:46","date_gmt":"2026-10-28T11:42:46","guid":{"rendered":"https:\/\/biocytara.com\/?page_id=23"},"modified":"2026-11-01T13:18:26","modified_gmt":"2026-11-01T13:18:26","slug":"about","status":"publish","type":"page","link":"https:\/\/biocytara.com\/?page_id=23","title":{"rendered":"ABOUT"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"23\" class=\"elementor elementor-23\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-335de955 e-flex e-con-boxed e-con e-parent\" data-id=\"335de955\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-19ac7a89 e-con e-atomic-element e-flexbox-base e-default-div e-19ac7a89-043537f \" data-id=\"19ac7a89\" data-element_type=\"e-flexbox\" data-e-type=\"e-flexbox\" data-interaction-id=\"19ac7a89\" data-e-type=\"e-flexbox\" data-id=\"19ac7a89\">\n    \t\t<div class=\"elementor-element elementor-element-42c62a0d elementor-widget elementor-widget-spacer\" data-id=\"42c62a0d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5b0b476f elementor-widget elementor-widget-text-editor\" data-id=\"5b0b476f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h1>About BioCytara<\/h1>\t\t\t\t\t\t\t\t<\/div>\n\t\t\n<\/div>\n\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-7e20695e e-flex e-con-boxed e-con e-parent\" data-id=\"7e20695e\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-645af6a5 e-con e-atomic-element e-flexbox-base e-default-div e-645af6a5-d27ab50 \" data-id=\"645af6a5\" data-element_type=\"e-flexbox\" data-e-type=\"e-flexbox\" data-interaction-id=\"645af6a5\" data-e-type=\"e-flexbox\" data-id=\"645af6a5\">\n    \t\t<div class=\"elementor-element elementor-element-770c228c elementor-widget elementor-widget-spacer\" data-id=\"770c228c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<h2 data-interaction-id=\"41e4b4\" class=\"e-heading-base e-default-h2\" data-e-type=\"widget\" data-id=\"41e4b4\"><strong>Science-Driven Innovation. Patient-Focused Development.<\/strong><\/h2>\n\t\t\t\t<div class=\"elementor-element elementor-element-2212374f elementor-widget elementor-widget-text-editor\" data-id=\"2212374f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Our mission is to advance cancer therapies that combine meaningful antitumor activity with improved treatment tolerability, addressing the needs of patients who cannot receive conventional intensive cancer therapy.<\/p><p>Our lead development program centers on <strong>Aspacytarabine<\/strong> (BST-236), an investigational cytarabine prodrug with an established clinical research history and promising results in patients with acute myeloid leukemia.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1f03f0b4 elementor-widget elementor-widget-spacer\" data-id=\"1f03f0b4\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<h2 data-interaction-id=\"6c4fa332\" class=\"e-heading-base e-default-h2\" data-e-type=\"widget\" data-id=\"6c4fa332\"><strong>Our Mission<\/strong><\/h2>\n\t\t\t\t<div class=\"elementor-element elementor-element-6d16087a elementor-widget elementor-widget-text-editor\" data-id=\"6d16087a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>To develop innovative cancer treatments that address significant unmet medical needs by improving drug delivery, reducing treatment-limiting toxicity, and expanding therapeutic opportunities.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1b276d5d elementor-widget elementor-widget-spacer\" data-id=\"1b276d5d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<h2 data-interaction-id=\"53fd4bd\" class=\"e-heading-base e-default-h2\" data-e-type=\"widget\" data-id=\"53fd4bd\"><strong>Our Vision<\/strong><\/h2>\n\t\t\t\t<div class=\"elementor-element elementor-element-dc40793 elementor-widget elementor-widget-text-editor\" data-id=\"dc40793\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>To become a recognized biopharmaceutical company specializing in differentiated cancer therapies that improve the balance between efficacy, safety, and patient quality of life.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-ceb0695 elementor-widget elementor-widget-spacer\" data-id=\"ceb0695\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<h2 data-interaction-id=\"e3fa8a3\" class=\"e-heading-base e-default-h2\" data-e-type=\"widget\" data-id=\"e3fa8a3\"><strong>Our Story<\/strong><\/h2>\n\t\t\t\t<div class=\"elementor-element elementor-element-c48d91e elementor-widget elementor-widget-text-editor\" data-id=\"c48d91e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>Aspacytarabine originated from a scientific approach to improving the therapeutic characteristics of cytarabine, one of the most widely used chemotherapy agents in hematological malignancies.<\/p><p>Through years of pharmaceutical research and clinical development originally undertaken by BioSight, Aspacytarabine progressed from drug design and preclinical evaluation to clinical studies involving patients with AML.<\/p><p>These studies generated valuable evidence supporting the potential of Aspacytarabine to deliver clinically active cytarabine exposure in patient populations traditionally considered unsuitable for intensive cancer therapy.<\/p><p>BioCytara&#8217;s strategy builds upon this scientific and clinical foundation, focusing on further development, regulatory advancement, and the potential commercialization of Aspacytarabine.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-8d9f352 elementor-widget elementor-widget-spacer\" data-id=\"8d9f352\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<h2 data-interaction-id=\"45f0017\" class=\"e-heading-base e-default-h2\" data-e-type=\"widget\" data-id=\"45f0017\"><strong>Our Development Strategy<\/strong><\/h2>\n\t\t\t\t<div class=\"elementor-element elementor-element-f1042d6 elementor-widget elementor-widget-text-editor\" data-id=\"f1042d6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>BioCytara intends to pursue a milestone-driven development program.<\/p><p>Our near-term objectives include advancing a pivotal clinical development strategy for Aspacytarabine in Israel, engaging with regulatory authorities, and preparing the pharmaceutical and clinical infrastructure needed for registration.<\/p><p>Our longer-term strategy includes pursuing regulatory pathways in Europe and United States, expanding potential applications of Aspacytarabine, and establishing international pharmaceutical partnerships.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1423a20 elementor-widget elementor-widget-spacer\" data-id=\"1423a20\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<h2 data-interaction-id=\"9abd7e1\" class=\"e-heading-base e-default-h2\" data-e-type=\"widget\" data-id=\"9abd7e1\"><strong>Our Commitment<\/strong><\/h2>\n\t\t\t\t<div class=\"elementor-element elementor-element-7b79eb5 elementor-widget elementor-widget-text-editor\" data-id=\"7b79eb5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p>BioCytara is committed to responsible scientific development, clinical research integrity, and transparent communication.<\/p><p>We recognize that bringing new treatments to patients requires rigorous evidence, strong clinical partnerships, regulatory compliance, and continued investment in research.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<h2 data-interaction-id=\"bc82ecb\" class=\"e-heading-base e-default-h2\" data-e-type=\"widget\" data-id=\"bc82ecb\"><strong>Our ultimate objective is to translate pharmaceutical innovation into meaningful benefits for patients facing life-threatening diseases.<\/strong><\/h2>\n\t\t\t\t<div class=\"elementor-element elementor-element-720ec44 elementor-widget elementor-widget-spacer\" data-id=\"720ec44\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\n<\/div>\n\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>About BioCytara Science-Driven Innovation. Patient-Focused Development. Our mission is to advance cancer therapies that combine meaningful antitumor activity with improved treatment tolerability, addressing the needs of patients who cannot receive conventional intensive cancer therapy. Our lead development program centers on Aspacytarabine (BST-236), an investigational cytarabine prodrug with an established clinical research history and promising results [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"footnotes":""},"class_list":["post-23","page","type-page","status-publish","hentry"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.4 - aioseo.com -->\n\t<meta name=\"description\" content=\"About BioCytara Science-Driven Innovation. Patient-Focused Development. Our mission is to advance cancer therapies that combine meaningful antitumor activity with improved treatment tolerability, addressing the needs of patients who cannot receive conventional intensive cancer therapy.Our lead development program centers on Aspacytarabine (BST-236), an investigational cytarabine prodrug with an established clinical research history and promising results in\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<link rel=\"canonical\" href=\"https:\/\/biocytara.com\/?page_id=23\" \/>\n\t\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.4\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_US\" \/>\n\t\t<meta property=\"og:site_name\" content=\"BioCytara - Rethinking Cancer therapy. Advancing Leukemia Treatment.\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"ABOUT - BioCytara\" \/>\n\t\t<meta property=\"og:description\" content=\"About BioCytara Science-Driven Innovation. Patient-Focused Development. Our mission is to advance cancer therapies that combine meaningful antitumor activity with improved treatment tolerability, addressing the needs of patients who cannot receive conventional intensive cancer therapy.Our lead development program centers on Aspacytarabine (BST-236), an investigational cytarabine prodrug with an established clinical research history and promising results in\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/biocytara.com\/?page_id=23\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/biocytara.com\/wp-content\/uploads\/2026\/10\/LogoV4.png\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/biocytara.com\/wp-content\/uploads\/2026\/10\/LogoV4.png\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2026-10-28T11:42:46+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-11-01T13:18:26+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"ABOUT - BioCytara\" \/>\n\t\t<meta name=\"twitter:description\" content=\"About BioCytara Science-Driven Innovation. Patient-Focused Development. Our mission is to advance cancer therapies that combine meaningful antitumor activity with improved treatment tolerability, addressing the needs of patients who cannot receive conventional intensive cancer therapy.Our lead development program centers on Aspacytarabine (BST-236), an investigational cytarabine prodrug with an established clinical research history and promising results in\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/biocytara.com\/wp-content\/uploads\/2026\/10\/LogoV4.png\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/biocytara.com\\\/?page_id=23#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/biocytara.com\\\/#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/biocytara.com\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/biocytara.com\\\/?page_id=23#listItem\",\"name\":\"ABOUT\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/biocytara.com\\\/?page_id=23#listItem\",\"position\":2,\"name\":\"ABOUT\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/biocytara.com\\\/#listItem\",\"name\":\"Home\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/biocytara.com\\\/#organization\",\"name\":\"BioCytara\",\"description\":\"Rethinking Cancer therapy. Advancing Leukemia Treatment.\",\"url\":\"https:\\\/\\\/biocytara.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/biocytara.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/LogoV4.png\",\"@id\":\"https:\\\/\\\/biocytara.com\\\/?page_id=23\\\/#organizationLogo\",\"width\":883,\"height\":274},\"image\":{\"@id\":\"https:\\\/\\\/biocytara.com\\\/?page_id=23\\\/#organizationLogo\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/biocytara.com\\\/?page_id=23#webpage\",\"url\":\"https:\\\/\\\/biocytara.com\\\/?page_id=23\",\"name\":\"ABOUT - BioCytara\",\"description\":\"About BioCytara Science-Driven Innovation. Patient-Focused Development. Our mission is to advance cancer therapies that combine meaningful antitumor activity with improved treatment tolerability, addressing the needs of patients who cannot receive conventional intensive cancer therapy.Our lead development program centers on Aspacytarabine (BST-236), an investigational cytarabine prodrug with an established clinical research history and promising results in\",\"inLanguage\":\"en-US\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/biocytara.com\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/biocytara.com\\\/?page_id=23#breadcrumblist\"},\"datePublished\":\"2026-10-28T11:42:46+00:00\",\"dateModified\":\"2026-11-01T13:18:26+00:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/biocytara.com\\\/#website\",\"url\":\"https:\\\/\\\/biocytara.com\\\/\",\"name\":\"BioCytara\",\"description\":\"Rethinking Cancer therapy. Advancing Leukemia Treatment.\",\"inLanguage\":\"en-US\",\"publisher\":{\"@id\":\"https:\\\/\\\/biocytara.com\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"ABOUT - BioCytara","description":"About BioCytara Science-Driven Innovation. Patient-Focused Development. Our mission is to advance cancer therapies that combine meaningful antitumor activity with improved treatment tolerability, addressing the needs of patients who cannot receive conventional intensive cancer therapy.Our lead development program centers on Aspacytarabine (BST-236), an investigational cytarabine prodrug with an established clinical research history and promising results in","canonical_url":"https:\/\/biocytara.com\/?page_id=23","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/biocytara.com\/?page_id=23#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/biocytara.com\/#listItem","position":1,"name":"Home","item":"https:\/\/biocytara.com\/","nextItem":{"@type":"ListItem","@id":"https:\/\/biocytara.com\/?page_id=23#listItem","name":"ABOUT"}},{"@type":"ListItem","@id":"https:\/\/biocytara.com\/?page_id=23#listItem","position":2,"name":"ABOUT","previousItem":{"@type":"ListItem","@id":"https:\/\/biocytara.com\/#listItem","name":"Home"}}]},{"@type":"Organization","@id":"https:\/\/biocytara.com\/#organization","name":"BioCytara","description":"Rethinking Cancer therapy. Advancing Leukemia Treatment.","url":"https:\/\/biocytara.com\/","logo":{"@type":"ImageObject","url":"https:\/\/biocytara.com\/wp-content\/uploads\/2026\/10\/LogoV4.png","@id":"https:\/\/biocytara.com\/?page_id=23\/#organizationLogo","width":883,"height":274},"image":{"@id":"https:\/\/biocytara.com\/?page_id=23\/#organizationLogo"}},{"@type":"WebPage","@id":"https:\/\/biocytara.com\/?page_id=23#webpage","url":"https:\/\/biocytara.com\/?page_id=23","name":"ABOUT - BioCytara","description":"About BioCytara Science-Driven Innovation. Patient-Focused Development. Our mission is to advance cancer therapies that combine meaningful antitumor activity with improved treatment tolerability, addressing the needs of patients who cannot receive conventional intensive cancer therapy.Our lead development program centers on Aspacytarabine (BST-236), an investigational cytarabine prodrug with an established clinical research history and promising results in","inLanguage":"en-US","isPartOf":{"@id":"https:\/\/biocytara.com\/#website"},"breadcrumb":{"@id":"https:\/\/biocytara.com\/?page_id=23#breadcrumblist"},"datePublished":"2026-10-28T11:42:46+00:00","dateModified":"2026-11-01T13:18:26+00:00"},{"@type":"WebSite","@id":"https:\/\/biocytara.com\/#website","url":"https:\/\/biocytara.com\/","name":"BioCytara","description":"Rethinking Cancer therapy. Advancing Leukemia Treatment.","inLanguage":"en-US","publisher":{"@id":"https:\/\/biocytara.com\/#organization"}}]},"og:locale":"en_US","og:site_name":"BioCytara - Rethinking Cancer therapy. Advancing Leukemia Treatment.","og:type":"article","og:title":"ABOUT - BioCytara","og:description":"About BioCytara Science-Driven Innovation. Patient-Focused Development. Our mission is to advance cancer therapies that combine meaningful antitumor activity with improved treatment tolerability, addressing the needs of patients who cannot receive conventional intensive cancer therapy.Our lead development program centers on Aspacytarabine (BST-236), an investigational cytarabine prodrug with an established clinical research history and promising results in","og:url":"https:\/\/biocytara.com\/?page_id=23","og:image":"https:\/\/biocytara.com\/wp-content\/uploads\/2026\/10\/LogoV4.png","og:image:secure_url":"https:\/\/biocytara.com\/wp-content\/uploads\/2026\/10\/LogoV4.png","article:published_time":"2026-10-28T11:42:46+00:00","article:modified_time":"2026-11-01T13:18:26+00:00","twitter:card":"summary_large_image","twitter:title":"ABOUT - BioCytara","twitter:description":"About BioCytara Science-Driven Innovation. Patient-Focused Development. Our mission is to advance cancer therapies that combine meaningful antitumor activity with improved treatment tolerability, addressing the needs of patients who cannot receive conventional intensive cancer therapy.Our lead development program centers on Aspacytarabine (BST-236), an investigational cytarabine prodrug with an established clinical research history and promising results in","twitter:image":"https:\/\/biocytara.com\/wp-content\/uploads\/2026\/10\/LogoV4.png"},"aioseo_meta_data":{"post_id":"23","title":null,"description":null,"keywords":null,"keyphrases":{"focus":{"keyphrase":"","score":0,"analysis":{"keyphraseInTitle":{"score":0,"maxScore":9,"error":1}}},"additional":[]},"focus_keyword":null,"additional_keywords":null,"truseo_locale":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_custom_url":null,"og_image_custom_fields":null,"og_image_url":null,"og_image_width":null,"og_image_height":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_image_url":null,"twitter_title":null,"twitter_description":null,"schema_type":"default","schema_type_options":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"WebPage","isEnabled":true},"graphs":[]},"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"large","priority":null,"frequency":"default","local_seo":null,"limit_modified_date":false,"ai":{"faqs":[],"keyPoints":[],"schemas":[],"titles":[],"descriptions":[],"socialPosts":{"email":{"subject":"","preview":"","content":""},"linkedin":[],"twitter":[],"facebook":[],"instagram":[]}},"breadcrumb_settings":null,"seo_analyzer_scan_date":null,"created":"2026-10-28 11:42:47","updated":"2026-11-01 14:04:30"},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/biocytara.com\/\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tABOUT\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/biocytara.com\/"},{"label":"ABOUT","link":"https:\/\/biocytara.com\/?page_id=23"}],"_links":{"self":[{"href":"https:\/\/biocytara.com\/index.php?rest_route=\/wp\/v2\/pages\/23","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biocytara.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/biocytara.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/biocytara.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/biocytara.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23"}],"version-history":[{"count":4,"href":"https:\/\/biocytara.com\/index.php?rest_route=\/wp\/v2\/pages\/23\/revisions"}],"predecessor-version":[{"id":156,"href":"https:\/\/biocytara.com\/index.php?rest_route=\/wp\/v2\/pages\/23\/revisions\/156"}],"wp:attachment":[{"href":"https:\/\/biocytara.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}